PCK1 and nonpapillary renal cell carcinoma: PCK1 is downstream of the mTOR pathway [9]; mTOR inhibition up-regulates PCK1 and shuttles glycolytic flux to the gluconeogenesis pathway, thereby inhibiting cellular proliferation in hepatocellular carcinoma and ccRCC [30].